Summary of Study ST000465

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000357. The data can be accessed directly via it's Project DOI: 10.21228/M8WW32 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST000465
Study Title	Uniquely Tumor-Selective Englerin A Profoundly Alters Lipid Metabolism in Renal Cell Carcinoma inducing ER-Stress and an Acute Inflammatory Response
Study Type	Metabolomic effect of Englerin A on renal cell carcinoma
Study Summary	This targeted metabolomic analysis was performed on renal cell carcinoma A498 cells with or without anti-cancer drug Englerin treatment for 24 and 48 h.
Institute	University of California, San Diego
Department	Department of Pediatrics
Last Name	Batova
First Name	Ayse
Address	La Jolla, CA 92093
Email	abatova@ucsd.edu
Phone	619-543-1962
Submit Date	2016-09-09
Num Groups	Two groups for 24 h treatment (control and Eglerin treatment) and two groups for 48 h treatment. Each has 4 replicates
Total Subjects	16
Analysis Type Detail	LC-MS
Release Date	2016-12-22
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR000500
Treatment Summary:	A498 cells were plated in 100mm dishes at 0.5 x 106 and 1 x 106 cells/dish in complete RPMI for control and treated cells, respectively. The following day, cells were refed with complete RPMI containing 0.1% DMSO or 100 nM englerin A in DMSO with each condition being conducted in quadruplicate. Cells were incubated with vehicle or englerin A for 24 or 48 h and then they were snap frozen with liquid nitrogen.
Treatment:	Anticaner drug
Treatment Compound:	Englerin A
Treatment Route:	Direct incubation
Treatment Dose:	100 nM
Treatment Doseduration:	24hr and 48hr